Back to Search Start Over

Birt-Hogg-Dubé syndrome: diagnosis and management

Authors :
Lennart Friis-Hansen
Fred H. Menko
Eamonn R. Maher
Sophie Giraud
Stéphane Richard
Thomas Hansen
Magnus Nordenskjöld
Maurice A.M. van Steensel
John Solly
Silvana Ungari
Human genetics
CCA - Innovative therapy
Source :
Lancet Oncology, 10(12), 1199-1206. Lancet Publishing Group, Menko, F H, van Steensel, M A M, Giraud, S, Friis-Hansen, L, Richard, S, Ungari, S, Nordenskjold, M, Hansen, T V, Solly, J & Maher, E R 2009, ' Birt-Hogg-Dube syndrome: diagnosis and management ', Lancet Oncology, vol. 10, no. 12, pp. 1199-1206 . https://doi.org/10.1016/S1470-2045(09)70188-3
Publication Year :
2009

Abstract

Summary Birt-Hogg-Dube syndrome (BHD) is an autosomal dominant condition characterised clinically by skin fibrofolliculomas, pulmonary cysts, spontaneous pneumothorax, and renal cancer. The condition is caused by germline mutations in the FLCN gene, which encodes folliculin; the function of this protein is largely unknown, although FLCN has been linked to the mTOR pathway. The availability of DNA-based diagnosis has allowed insight into the great variation in expression of FLCN , both within and between families. Patients can present with skin signs and also with pneumothorax or renal cancer. Preventive measures are aimed mainly at early diagnosis and treatment of renal cancer. This Review gives an overview of current diagnosis and management of BHD.

Details

ISSN :
14745488 and 14702045
Volume :
10
Issue :
12
Database :
OpenAIRE
Journal :
The Lancet. Oncology
Accession number :
edsair.doi.dedup.....0f48c1c488aaeee4d7e7986feb77855f